Study of triple-negative breast cancer is most cited in AACR journal

Drs. Joyce O’Shaughnessy of Baylor Scott & White Health and U.S. Oncology, from left, John Carpten, TGen’s deputy director of basic science and director of its Cancer Genomics Division, and David Craig, TGen’s deputy director of bioinformatics, are co-authors of the most-cited study in 2013 of any published that year by AACR’s journal Molecular Cancer Therapeutics. The paper describes potential drug targets following the unprecedented genomic sequencing of 14 metastatic triple-negative breast cancer patients.